reports
- Michiel Declercq
bpost Conference call feedback and model update post 2Q25
Despite the ongoing headwinds, bpost reported better than expected 2Q25 results, with the adj. EBIT of € 58.3m exceeding expectations (kbcse: € 46m, css: € 48m). While results in Belgium were somewhat lower, this was offset by better than expected results in the other divisions while Staci's performance was in line. Although sales pressure at Radial US continued following the termination of contracts in 2024 and early 2025, we are pleased to see that its new fast track offering is gaining tracti...
- Guy Sips
Jensen-Group Further enhancing its market position after an exceptiona...
We updated our model (New € 62 Target Price, Accumulate rating) after Jensen-Group's exceptional 1H25. Jensen-Group highlighted in its outlook statement it is aiming for 2H25, without giving exact numbers, to hold firm to its strategic course : driving customer centricity and sustainable innovation while further enhancing the optimization and digitalization of business processes and applications. We incorporated in our updated model Jensen-Group's targeted investments in expanding production c...
- Kristof Samoy
Vopak FID on new LPG greenfield terminal by Indian JV AVTL
42% owned AVTL announced a €170m investment in a greenfield LPG terminal and bottling plant. LPG demand in India has grown at a 7.3% CAGR over the past decade with further attractive growth in demand and terminal imports expected. The Indian JV AVTL was recently listed and the IPO proceeds amounted to ca. €290m to be deployed for debt repayment and further growth initiatives. The listing frees up cash at the Vopak holding which can be deployed for funding other investments or additional sharehol...
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
- Guy Sips
Lotus Bakeries FIRST LOOK : maintaining our € 10750 TP and increasing ...
In view of the significant volume growth Lotus Bakeries realised in FY24, the y/e consecutive volume increase of both Biscoff and Natural Foods was a testament to the strength of the different brands. The y/y increase of 1H25 REBITDA and REBIT of 11.7% and 12.6% respectively, outpace the top-line growth (9.7%) and confirms again the strength of Lotus Bakeries' operating model. The international growth engines of Biscoff and Natural Foods generate solid volume increases allowing to leverage its o...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Wim Lewi
- Wim Lewi
CTP 1H25 results show progress on pre-let despite tariff war
Gross Rental income grew 14.4% yoy to EUR 367.2m vs. 380.1m expected (KBCS) and benefited from strong 4.9% like-for-like growth. The EPRA EPS of 0.42 came slightly below our expectation of 0.43. New leases signed increased 11% yoy to 1m sqm. The FY25 EPS outlook is maintained at 0.86-0.88. The LTV% improved to 44.9% from 45.3%. The Cost of Debt increased to 3.20% vs. 3.09% at FY24-end. The occupancy on standing assets was flat at 93% vs. FY24 end. CTP maintained its development pipeline to a rec...
- Wim Lewi
Warehouses De Pauw Tony De Pauw has passed away
Yesterday, Tony De Pauw of the founding family passed away unexpectedly at home. In June 1999, at WDP's IPO, Tony took over the helm from his father Jos De Pauw, founder of WDP. Together with WDP management, he built WDP into a leading European family-rooted logistics platform. Tony stepped down from his role as co-CEO in 2024, a position he had shared with Joost Uwents since 2010. During this time, he remained active as a Board member. On 30/6, the family shareholding declined below 20.0% to 19...
- Wim Lewi
Xior 1H25 results, in line, shifting back to pipeline growth
Xior reported EPRA EPS of 1.01 that slightly beat our 1.00 expectation (excl. IFRIC costs). Xior NRI rose 4.0% yoy after its disposal program of FY24, but like-for-like growth remained high at 5.4%. LTV% also fell below 50% at 49.8%. Xior repeated its flat EPRA EPS outlook for FY25 of 2.21 per share. Xior expects an underlying strong FY25 thanks to a mix of factors: new assets + lfl growth of >5% and cost savings. The cost of debt decreased slightly from 3.10% (FY24) to 3.03%. The asset disposal...
- Jacob Mekhael
argenx Upping our FY25 estimates after a solid 2Q25 beat
Following argenx' 2Q25 results with Vyvgart sales coming in at $ 949m, and beating CSS by 10%, we update our model, upping our Vyvgart sales estimates for FY25 to $ 3.98b (from $ 3.61b, Visible Alpha CSS: $ 3.97b). We factor in potential competition from IMAAVY (J&J), though we continue to see Vyvgart as the better product, and model approx. 12% q/q growth for 3Q25 and 4Q25. Additionally, we slightly tweak our CIDP numbers bringing us to higher peak sales ($ 4.22b vs. $ 3.76b). All in all, our t...
- Kristof Samoy
Arcadis Guidance for moderate 2H25 growth prompts model revision
Arcadis released its 1H25 results last week. As anticipated, the Places segment continued to experience weakness due to ongoing uncertainty around capital expenditure programs. Resilience delivered strong margin performance, though topline growth and order intake decelerated. The UK segment declined 8%, impacted by the completion of HS2, the conclusion of the spending review in June, and the onset of the AMP8 cycle. On the analyst call, management guided for moderate growth in 2H25, diverging fr...
- Michiel Declercq
Ahold Delhaize 2Q25: Solid results with price investments paying off, ...
Ahold Delhaize reported a solid set of 2Q25 results, with comparable sales growth of 3.4% in the US (css: +3.1%) and +4.9% in the EU (css: +3.8%) exceeding expectations. While group margins contracted by 20bps to 4.0%, this was well anticipated on the back of ongoing price investments in the US and the dilutive impact from the consolidation of Profi in the EU. As such, the underlying group EBIT of € 917m came in slightly ahead of expectations (css: € 908m, css: € 905m). Following the solid 2Q25,...
- Jacob Mekhael
Galapagos Receives FDA RMAT designation for GLPG5101 in r/r MCL
Galapagos announced that the FDA has granted RMAT designation to GLPG5101 (CD19- CAR-T) to treat relapsed/refractory mantle cell lymphoma (r/r MCL). This is based on the strong data that GLPG5101 has demonstrated in the MCL cohort in the phase 1/2 (ATLANTA-1) trial in r/r NHL, and comes with a number of potential benefits including eligibility for accelerated approval, and could further support external discussions as Galapagos explores strategic alternatives for the cell therapy business. Accum...
- Jacob Mekhael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
- Lynn Hautekeete
Home Invest Belgium Taking the next steps Forward
We zoom in on the deal announced between HOMI and City Forward. HOMI will redevelop 8 offices into 700-750 apartments over the next 7-9 years. The deal will push the residential portfolio of HOMI over EUR 1.2B. We assume a total investment of EUR 280.0m, 20% development margin and EUR 14.0m gross rental income. We are very supportive of this deal but the gains on the development are back-end loaded while we see a short term headwind in a building right expiry in Louvain La Neuve (10.9% rents). ...
- Livio Luyten
Holdings Report - July 2025 KBCS Holdings Universe Returns -0.5% Durin...
1M Performance - Absolute Total Return: During Jul'25 (1M period), the KBCS Holdings Universe posted a total return of -0.5% which was mainly driven by the performance of the multi-asset holdings (-0.9%), while the single-asset holdings posted a return of +0.4%. The 3 top performers during the period were Financière de Tubize (+11.7%), KBC Ancora (+9.4%) and Quest For Growth (+5.5%) while the 3 worst performers were Brederode (-6.4%), Heineken Holding (-5.0%) and D'Ieteren Group (-4.7%). YTD Pe...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
EXO EXOR N.V.
- Thomas Couvreur
NN Group Increase FY26-FY27 estimates leading to higher TP; further up...
We have reviewed our NN Group model, adjusting our estimates for FY26-FY27, leaving FY25 largely unchanged. This has resulted in an increase of TP from €53 to €61. The biggest impact is coming from incorporating a more gradual growth towards the 2.2bn OCG target by FY28, rather than back-end loading the benefits. Given the very strong rally the stock has made since the beginning of the year, gaining 40%, we see a more limited upside going forward. We move our rating from Buy to Accumulate.
- Guy Sips
- Kristof Samoy
- Michiel Declercq
- Michiel Declercq
JDE Peets 1H25 results confirm coffee's positioning as a staple good
Last week Wednesday, JDE Peet's surprised with a strong set of 1H25 results, with the vol/mix increasing 1.0% despite a significant price increase of 21.5%. While the vol/mix effect was positively impacted by around 2-3% from customers pre-buying ahead of further anticipated price hikes, the underlying price elasticity remains resilient. This reconfirms coffee's positioning as a staple good. While price elasticity is expected to slightly deteriorate in 2H25, it should remain at healthy levels. A...
- Wim Hoste
Titan Teaming up with Molins for the joint acquisition of Baupartner
The proposed joint acquisition of Baupartner further enlarges TITAN's product portfolio with value-added concrete-based structural solutions in Southeast Europe, a region where TITAN is already well established. We remind that Titan recently reported resilient 1H25 results with EBITDA up 2% y/y, which was about 1% better than our forecast. We continue to remain optimistic on TITAN's prospects in the US and remind that only one third of Titan America's sales is imported in the US (with future tar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.